What is it about?
The article presents a risk prediction model for long-term heart failure incidence for breast cancer patient treated with epirubicin chemotherapy. It suggests an additive score system to calculate the risk for each patient. With the help of the scoring system, the risk of the development of heart failure can be estimated during chemotherapy.
Featured Image
Why is it important?
Our analysis carried out on large nation-wide databases reflects the current clinical practice. By calculating the score points derived from clinical data, the surveillance and treatment of the patients can be individualized to reach the optimal outcome.
Read the Original
This page is a summary of: Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer – A real-world data-based, nationwide classification analysis, International Journal of Cardiology, June 2019, Elsevier,
DOI: 10.1016/j.ijcard.2019.03.013.
You can read the full text:
Contributors
The following have contributed to this page
